Endlyz Therapeutics
PrivateLast Round
Seed
May 7, 2026
Total Funding Raised
$18.2M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Endlyz Therapeutics is a biotechnology company developing disease-modifying small-molecule therapeutics to restore endo-lysosomal function for the treatment of Parkinson's disease and other neurodegenerative disorders.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Endlyz Therapeutics Comparables
Compare Endlyz Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Retromer Therapeutics | 84% | |
| Alectos Therapeutics | 78% | |
| Scenic Biotech | 76% | |
Endlyz Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 7, 2026 | ||||
| Seed | Mar 31, 2025 | ||||
| Grant | Mar 31, 2025 |
Endlyz Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Seed |
| Parkinson's UK | Seed |
| Oxford Science Enterprises | Seed |
| Centre for Drug Design and Discovery | Seed |
| AbbVie Ventures | Seed |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
| Oxford Science Enterprises | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 7, 2026
Raised $17.25M in early stage venture capital.
- Mar 31, 2025
Received $2.2M from The Michael J. Fox Foundation.
Endlyz Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Endlyz Therapeutics's valuation, stock price, and market status.